DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
This grant funds early-phase clinical trials for ALS that use biomarkers or improve clinical care, requiring community collaboration, a regulatory strategy, and a plan for advancing study results.
Funder: Dept. of the Army -- USAMRAA
Due Dates: June 24, 2026 (Pre-Application) | September 30, 2026 (Full Application) | October 6, 2026 (End of Application Verification)
Funding Amounts: ~$5.6M total; up to $2.8M per award (direct + indirect) for up to 3 years; ~2 awards expected
Summary: Supports rapid implementation of pilot clinical trials with significant impact on ALS treatment or management, focusing on biomarker-driven interventions or clinical care.
Key Information: Pre-application required; only invited applicants may submit full proposals; community collaboration is mandatory.
Description
This funding opportunity supports pilot clinical trials aimed at accelerating advances in the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials and must focus on either biomarker-driven interventions (using mechanism-specific biomarkers to inform trial design and outcomes) or improvements in clinical care and symptom management for ALS patients. The program requires the integration of community collaboration to ensure research is responsive to the needs of people living with ALS, their families, and care partners.
